Development of oral anticoagulants.
Ma
Qing
Q
Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, USA. quingma@buffalo.edu
D000284:Administration, Oral; D000925:Anticoagulants / Q000008:administration & dosage / Q000494:pharmacology*; D001384:Azetidines / Q000494:pharmacology; D001562:Benzimidazoles / Q000494:pharmacology; D001596:Benzylamines / Q000494:pharmacology; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D000069604:Dabigatran; D016503:Drug Delivery Systems; D015195:Drug Design; D017984:Enoxaparin / Q000494:pharmacology; D065427:Factor Xa Inhibitors; D006801:Humans; D009025:Morpholines / Q000494:pharmacology; D019106:Postoperative Hemorrhage / Q000517:prevention & control; D011725:Pyridines / Q000494:pharmacology; D000069552:Rivaroxaban; D013876:Thiophenes / Q000494:pharmacology; D054556:Venous Thromboembolism / Q000517:prevention & control; D020246:Venous Thrombosis / Q000517:prevention & control; D014859:Warfarin / Q000494:pharmacology
D000925:Anticoagulants; D001384:Azetidines; D001562:Benzimidazoles; D001596:Benzylamines; D017984:Enoxaparin; D065427:Factor Xa Inhibitors; D009025:Morpholines; D011725:Pyridines; D013876:Thiophenes; C426686:ximelagatran; D014859:Warfarin; D000069552:Rivaroxaban; D000069604:Dabigatran